| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d0f6c13ec4053e0b1e772446f23ba37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722744e77c81c5f5cf415087e2ee92b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5e95156255d5fe8b2923c544786e176 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-026 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1205 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2000-06-05^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2001-04-03^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57e08bce152dcfc8b9682106e056c89b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90cc939eca63d2796149ced224909f59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8aaa53ca4ea069eb8ac1966fb2bc4bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8c787be14ba32b2f19094ece22043e0 |
| publicationDate |
2001-04-03^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6210916-B1 |
| titleOfInvention |
Rec 2 kinase |
| abstract |
The invention includes a method of phosphorylating a serine containing substrate by incubating the substrate with ATP and an enzyme that is hsRec2 or muRec2 or a derivative thereof. The natural substrates of the kinase activity of Rec2 are the cell cycle control proteins such as p53 and cyclin E. The over expression of Rec2 is known to cause cell-cycle arrest and apoptosis and the invention discloses that these effects are kinase mediated. Accordingly, the invention provides a method of assessing antagonists and agonists of Rec2, which antagonists and agonists would have pharmacological activity. The invention further discloses that there is specific binding between hsRec2 and at least three cell cycle control proteins: p53, PCNA and cdc2. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11160224-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005177899-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008256668-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10035991-B2 |
| priorityDate |
1998-09-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |